|
Thank you for
your continued interest in "Disease Modification
in IBD: Exploring Current Clinical Opportunities", an event which
took place on May 21st, 2002. To view
the list of presentations click
here or on the "Go to Presentations" button at the bottom
of this page.
CME
Credits will be available online
during this program.
|
 |
|
Program Chair
Paul J. Rutgeerts,
MD, PhD
University Hospital Gasthuisberg
University of Leuven
Leuven, Belgium
Faculty
Stephen B.
Hanauer, MD
University of Chicago
Pritzker School of Medicine
Chicago, Illinois
Bruce E. Sands,
MD
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts
Panelists
Russell D.
Cohen, MD
University of Chicago
Pritzker School of Medicine
Chicago, Illinois
Zane Cohen,
MD, FRCS
Mount Sinai Hospital
Toronto, Ontario, Canada
Gary R. Lichtenstein,
MD
University of Pennsylvania
School of Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
|
Educational Objectives
Upon completion
of this
activity, the participant will be
able to:
• Discuss the clinical
challenges that gastroenterologists
encounter in the management of patients
with IBD
• Describe the potential role
of mucosal healing in disease modification
• Describe the effects on intestinal mucosa of
currently available medical therapies for CD
•
Identify therapeutic agents and
strategies that have demonstrated
benefits in the long-term management of
patients with CD
• Discuss treatment algorithms that may be shown
to improve outcomes in the future
• Discuss the clinical utility of conventional and
biologic therapies in fistulizing CD
• Identify the
most effective treatment strategies for this disease
complication
• Describe the appropriate
use of anti-TNF-a
therapy as maintenance
therapy for the treatment of inflammatory
and fistulizing CD
Target
Audience
This program has been designed
to meet the educational needs of
gastroenterologists and specialists
involved with the treatment of IBD.
|
|
